Loading
ID
Immune Design Corp. Stock: price and insider trades · United States
Immune Design Corp.: what insiders have been doing
Only a handful of insider records exist for Immune Design Corp., the last one from 6 January 2016, too few to describe a trend. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
5
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
n/a
Financial data
as of FY 2018FY ended December 2018 · cache
Income statement
Revenue2M
Net income-48.8M-2493.5% margin
Last declaration on 6 January 2016
Declarations5 total
15,000 sharesCommon StockSEC:0001123292-16-001531:0
12,000 sharesCommon StockSEC:0001123292-16-001533:0
7,000 sharesCommon StockSEC:0001123292-16-001535:0
36,000 sharesCommon StockSEC:0001123292-16-001537:0
12,000 sharesCommon StockSEC:0001123292-16-001539:0
5 of 5 declarations
About Immune Design Corp.
Immune Design Corp. is a biopharmaceutical company focused on developing immunotherapy treatments for cancer and infectious diseases. It is listed on NASDAQ under the ticker IMDZ.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
